Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v34-FR Version v20-FR
Language French French
Date Updated 2021-09-10 2020-06-18
Drug Identification Number 02330512 02330512
Brand name TEVA-IRBESARTAN HCTZ TEVA-IRBESARTAN HCTZ
Common or Proper name IRBESARTAN/HCTZ 150/12.5MG TAB IRBESARTAN/HCTZ 150/12.5MG TAB
Company Name TEVA CANADA LIMITED TEVA CANADA LIMITED
Ingredients HYDROCHLOROTHIAZIDE IRBESARTAN HYDROCHLOROTHIAZIDE IRBESARTAN
Strength(s) 12.5MG 150MG 12.5MG 150MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 100 100
ATC code C09DA C09DA
ATC description ANGIOTENSIN II ANTAGONISTS, COMBINATIONS ANGIOTENSIN II ANTAGONISTS, COMBINATIONS
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2019-12-18 2019-12-18
Estimated end date 2021-09-30 2020-08-31
Actual end date 2021-09-09
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments Allocating 100% of Teva market share from July to October 2020. Allocating to 100% of our market.
Health Canada comments